Multiple Myeloma Clinical Trials

A listing of 189 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 189 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

NCT05405387

Recruiting

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

Conditions: Multiple Myeloma

Learn More ›

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781

Recruiting

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona +45 locations

Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona

City of Hope, Duarte, California

University of California San Francisco, San Francisco, California

Stanford University Medical Center, Stanford, California

Emory University, Atlanta, Georgia

Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Kansas University Medical Center, Westwood, Kansas

Dana Farber Cancer Institute, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Washington University School Of Medicine, Saint Louis, Missouri

Hackensack University Medical Center, Hackensack, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Mount Sinai Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Levine Cancer Institute, Charlotte, North Carolina

University of Pennsylvania, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Froedtert Memorial, Milwaukee, Wisconsin

UZ Gent, Gent, Not set

UZ Leuven, Leuven, Not set

Peking University Third Hospital, Beijing, Not set

West China Hospital Si Chuan University, Chengdu, Not set

Fujian Medical University Union Hospital, Fuzhou, Not set

First Hospital, Zhejiang University Medical College, Hangzhou, Not set

Jiangsu Province Hospital, Nanjing, Not set

Ruijin Hospital Shanghai Jiao Tong University, Shanghai, Not set

Shanghai Fourth People s Hospital, Shanghai, Not set

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Not set

CHRU de Lille Hopital Claude Huriez, Nord, Not set

Hopital Saint Louis, Paris, Not set

Tel Aviv Sourasky Medical Center, Tel-Aviv, Not set

Nagoya City University Hospital, Nagoya, Not set

Japanese Red Cross Medical Center, Shibuya, Not set

VU Medisch Centrum, Amsterdam, Not set

University Medical Center Groningen, Groningen, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Hosp Clinico Univ de Salamanca, Salamanca, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study of Daratumumab

NCT05438043

Recruiting

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have... Read More

Gender:

ALL

Ages:

All

Trial Updated:

02/27/2025

Locations: University of Miami Sylvester Cancer Center, Miami, Florida +74 locations

University of Miami Sylvester Cancer Center, Miami, Florida

Emory University, Atlanta, Georgia

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

Barnes-jewish Hospital, Saint Louis, Missouri

Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Baylor University Medical Center, Dallas, Texas

ZNA Stuivenberg, Antwerpen, Not set

Peking Union Medical College Hospital, Beijing, Not set

Beijing Chaoyang Hospital, Beijing, Not set

Peking University First Hospital, Beijing, Not set

Peking University People s Hospital, Beijing, Not set

The First Bethune Hospital of Jilin University, Changchun, Not set

West China Hospital Si Chuan University, Chengdu, Not set

Fujian Medical University, Fuzhou, Not set

Guangdong General Hospital, Guangzhou, Not set

Nanfang Hospital, Guangzhou, Not set

First Affiliated Hospital Medical School of Zhejiang University, Hangzhou, Not set

First affiliated Hospital of Zhejiang University, Hangzhou, Not set

Shanghai Changzheng Hospital, Shanghai, Not set

Ruijin Hospital Shanghai Jiao Tong University, Shanghai, Not set

Renji Hospital, Shanghai Jiaotong University School of Medicine, ShangHai, Not set

First Affiliated Hospital SooChow University, Suzhou, Not set

Tianjin cancer hospital, Tianjin, Not set

Institute of Hematology and Blood Diseases Hospital, Tianjin, Not set

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Aarhus University Hospital, Aarhus N, Not set

Centre Hospitalier Universitaire (CHU) de Caen, Caen, Not set

CHU Nantes, Nantes Cedex 1, Not set

Hopital Saint Louis, Paris, Not set

Hopital Haut Leveque, Pessac, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Asklepios Klinik Altona, Hamburg, Not set

Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,, Tübingen, Not set

Alexandra General Hospital of Athens, Athens Attica, Not set

Anticancer Hospital of Thessaloniki Theageneio, Thessaloniki, Not set

Universita Degli Studi di Roma Tor Vergata, Roma, Not set

Sapienza University of Rome, Roma, Not set

Pusan National University Hospital, Busan, Not set

National Cancer Center, Goyang si, Not set

Chonnam National University Hwasun Hospital, Hwasun, Not set

Seoul National University Bundang Hospital, Seongnam, Not set

Seoul National University Hospital, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Wojewodzki Szpital Specjalistyczny w Legnicy, Legnica, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Not set

S.P. Botkin Moscow City Clinical Hospital, Moscow, Not set

Nizhniy Novgorod Region Clinical Hospital, Nizhny Novgorod, Not set

Republican Hospital named by V.A.Baranova, Petrozavodsk, Not set

Ryazan Regional Clinical Hospital, Ryazan, Not set

City Hospital No.15, Saint-Petersburg, Not set

Saratov State Medical University, Saratov, Not set

Clinical Research Institute of Hematology and Transfusiology, St-Petersburg, Not set

Oncology Dispensary of Komi Republic, Syktyvkar, Not set

Hosp. Univ. Germans Trias I Pujol, Badalona, Not set

Hosp Clinic de Barcelona, Barcelona, Not set

Inst. Cat. Doncologia-H Duran I Reynals, Hospitalet de Llobregat, Not set

Hosp. Univ. de Canarias, La Laguna, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Clinica Univ. de Navarra, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Centro Integral Oncológico Clara Campal, Madrid, Not set

Hosp. Gral. Univ. J.M. Morales Meseguer, Murcia, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Hosp Clinico Univ de Salamanca, Salamanca, Not set

Hosp. Univ. Dr. Peset, Valencia, Not set

Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council', Cherkasy, Not set

Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Not set

Kharkov Regional Clinical Oncology Center, Dept. of Hematology, Kharkov, Not set

Vinnytsya Regional Clinical Hospital named after M.I.Pirogov, Vinnitsa, Not set

St James University Hospital, Leeds, Not set

Royal Marsden Hospital, Surrey, Not set

Conditions: Multiple Myeloma

Learn More ›

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

NCT03761108

Recruiting

The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Sylvester Comprehensive Cancer Center, Miami, Florida +40 locations

Sylvester Comprehensive Cancer Center, Miami, Florida

Moffitt Cancer Center - McKinley Drive, Tampa, Florida

Emory University Hospital, Atlanta, Georgia

Indiana University_Michigan Street, Indianapolis, Indiana

Norton Cancer Institute, Louisville, Kentucky

C. S. Mott_University of Michigan, Ann Arbor, Michigan

Barbara Ann Karmanos Cancer Center, Detroit, Michigan

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Icahn School of Medicine at Mount Sinai, New York, New York

Columbia University Medical Center, New York, New York

Ohio State University James Cancer Hospital, Columbus, Ohio

Oregon Health and Science University (OHSU) Marquam Hill Campus, Portland, Oregon

University of Texas MD Anderson Clinic, Houston, Texas

Swedish Cancer Institute, Seattle, Washington

ZNA Psychiatrisch Ziekenhuis Stuivenberg, Antwerp, Not set

Cliniques Universitaires Saint-Luc, Bruxelles, Not set

Universitatsklinikum Essen, Essen, North Rhine-Westphalia

Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz, Rheinland-Pfalz

Universitatsklinikum Wurzburg, Würzburg, Not set

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi

Nagoya City University Hospital, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba-ken

Gunma University Hospital, Maebashi, Gunma

Ibaraki Prefectural Central Hospital, Kasama-shi, Ibaraki

University Hospital Kyoto Prefectural Univ of Medicine, Kyoto City, Kyoto

Saitama Medical University International Medical Center, Hidaka, Saitama

Japanese Red Cross Medical Center. 4-1-22 Hiroo, Shibuya-ku, Tokyo

Japanese Red Cross Medical Center, Shibuya-ku, Tokyo

Tokushima Prefectural Central Hospital. 1-10-3 Kuramoto-cho, Tokushima, Not set

Keio University Hospital, Tokyo, Not set

Center for Hematologic Malignancy, Goyang, Gyeonggi-do

Seoul National University Cancer Hospital, Seoul, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set

Yonsei University College of Medicine, Severance Hospital, Seoul, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia

Clinica Universidad de Navarra, Pamplona, Navarra

Universitary Hospital La Princesa, Madrid, Salamanca

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Clinico Universitario de Salamanca, Salamanca, Not set

Royal Marsden Hospital, Sutton, Surrey

Conditions: Multiple Myeloma

Learn More ›

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

NCT06106945

Recruiting

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2025

Locations: Research Site, Duarte, California +32 locations

Research Site, Duarte, California

Research Site, Irvine, California

Research Site, Atlanta, Georgia

Research Site, Boston, Massachusetts

Research Site, Ann Arbor, Michigan

Research Site, Saint Louis, Missouri

Research Site, New York, New York

Research Site, Philadelphia, Pennsylvania

Research Site, Fairfax, Virginia

Research Site, Melbourne, Not set

Research Site, Nedlands, Not set

Research Site, Hamilton, Ontario

Research Site, Ottawa, Ontario

Research Site, Montreal, Quebec

Research Site, Beijing, Not set

Research Site, Changsha, Not set

Research Site, Guangzhou, Not set

Research Site, Shenyang, Not set

Research Site, Lille, Not set

Research Site, Nantes, Not set

Research Site, Essen, Not set

Research Site, Freiburg, Not set

Research Site, Hamburg, Not set

Research Site, Lübeck, Not set

Research Site, Nürnberg, Not set

Research Site, Wuerzburg, Not set

Research Site, Kashiwa, Not set

Research Site, Nagoya-shi, Not set

Research Site, Yamagata-shi, Not set

Research Site, Madrid, Not set

Research Site, Pamplona, Not set

Research Site, Salamanca, Not set

Conditions: Multiple Myeloma

Learn More ›

A Study to Identify Barriers to Cellular Therapies for People with Plasma Cell Disorders

NCT06126341

Recruiting

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

02/24/2025

Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations

Conditions: Multiple Myeloma

Learn More ›

A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization

NCT06547112

Recruiting

This study includes extended CD34+ profiling on the apheresis product of multiple myeloma patients undergoing standard-of-care quad-induction followed by motixafortide + G-CSF mobilization, and in addition, assesses the pharmacodynamics (PD) of motixafortide following "standard" (\~12 hours) vs "early" (\~16 hours) dosing. The investigators hypothesize that quad-induction may alter the stem cell subsets within the mobilized graft. The investigators further hypothesize that standard and early dos... Read More

Gender:

ALL

Ages:

Between 18 years and 78 years

Trial Updated:

02/20/2025

Locations: Washington University School of Medicine, Saint Louis, Missouri

Conditions: Multiple Myeloma

Learn More ›

Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

NCT06142396

Recruiting

The goal of this study is to assess the efficacy of induction treatment with daratumumab-hyaluronidase (dara SC) with cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) for four cycles in patients with newly diagnosed multiple myeloma who have new onset renal failure. This study will also investigate the difference responses in African American (AA) patients versus non-African American patients. The primary questions this study aims to answer are: 1. To evaluate the very good partia... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

02/20/2025

Locations: Georgia Cancer Center-Augusta University, Augusta, Georgia

Conditions: Multiple Myeloma, Renal Failure

Learn More ›

A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant

NCT05393804

Recruiting

The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell transplant.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: Memorial Sloan Kettering Cancer Center, New York, New York

Conditions: Multiple Myeloma

Learn More ›

A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

NCT06559709

Recruiting

This clinical trial evaluates the impact of a plant-based whole-foods delivery service on the microbiome in patients with multiple myeloma undergoing an autologous hematopoietic cell transplant. An autologous hematopoietic cell transplant is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Loss of microbial diversity within the intestinal tract has been associated with poor outcomes for patients... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Multiple Myeloma

Learn More ›

Teclistamab or Talquetamab in Combination with Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)

NCT06100237

Recruiting

The purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/17/2025

Locations: University of Miami, Miami, Florida

Conditions: Multiple Myeloma

Learn More ›

Determining The Impact Of Distance Reiki On Patient Reported QOL And Immunity Among Multiple Myeloma Patients

NCT04783038

Recruiting

This research study is being done to determine if Distance Reiki therapy offers a quality of life benefit, and improves immunity compared to patients receiving Sham Distance Reiki therapy or no additional Reiki intervention.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/17/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Multiple Myeloma, Autologous Stem Cell Transplant

Learn More ›